Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2016-11-17 | DCVax®-L and pembrolizumab (Keytruda®) | colorectal cancer with liver metastases | 2 | Northwest Biotherapeutics (USA - MD) | Cancer - Oncology |
2016-11-17 | IMR-687 - 6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one | sickle cell disease | 1 | Imara (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
2016-11-17 | Praluent® (alirocumab - SAR236553/REGN727) | acute coronary syndrome | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases - Genetic diseases - Rare diseases |
2016-11-16 | sarilumab (REGN88/SAR153191) | rheumatoid arthritis | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-11-16 | buparlisib (BKM120) | metastatic breast cancer HR+, HER2- | 3 | Novartis (Switzerland) | Cancer - Oncology |
2016-11-16 | BI 695502 (biosimilar version of bevacizumab - Avastin®) | 1 | Boehringer Ingelheim (Germany) | Cancer - Oncology | |
2016-11-16 | BI 695502 (biosimilar version of bevacizumab - Avastin®) | non-small cell lung cancer (NSCLC) | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
2016-11-16 | momelotinib | myelofibrosis | 3 | Gilead Sciences (USA - CA) | Cancer - Oncology |
2016-11-15 | IONIS-ANGPTL3Rx | dyslipidemia |
1-2 | Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) | Cardiovascular diseases - Metabolic diseases |
2016-11-15 | IMMU-140 | preclinical | Immunomedics (USA - NJ) | Cancer - Oncology | |
2016-11-14 | ARC-F12 | hereditary angioedema, thrombosis | preclinical | Arrowhead Pharmaceuticals (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
2016-11-14 | ARC-LPA | preclinical | Arrowhead Pharmaceuticals (USA - CA) | Cardiovascular diseases | |
2016-11-14 | GALE-301 GALE-302 (Folate Binding Protein (FBP)) | breast cancer, ovarian cancer | 1-2 | Galena Biopharma (USA - OR) | Cancer - Oncology |
2016-11-14 | selonsertib (GS-4997) | NASH (non-alcoholic steatohepatitis) | 2 | Gilead Sciences (USA - CA) | Liver diseases - Hepatic diseases |
2016-11-14 | Resunab™- JBT-101 - (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid | diffuse cutaneous systemic sclerosis | 2 - open-label extension | Corbus Pharmaceuticals (USA - MA) | Rare diseases - Autoimmune diseases |
2016-11-14 | baricitinib (LY3009104) | rheumatoid arthritis |
3 | Eli Lilly (USA - IN) Incyte Corporation (USA - DE) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-11-14 | TG1050 | chronic hepatitis B | preclinical | Transgene (France) | Infectious diseases |
2016-11-14 | phosphatidylserine (PS)-targeting antibodies similar to bavituximab, anti-PD1 therapies, anti-LAG3 therapies and radiation therapies | preclinical | Peregrine Pharmaceuticals (USA - CA) | Cancer - Oncology | |
2016-11-14 | CDX-1140 | preclinical | Celldex Therapeutics (USA - NJ) | Cancer - Oncology | |
2016-11-14 | INO-3112 | head and neck squamous cell cancer | 1-2 | Inovio Pharmaceuticals (USA - PA) University of Pennsylvania (USA - PA) | Cancer - Oncology |